(Q42685193)

4 November 2017

title

Relapses in patients treated with fingolimod after previous exposure to natalizumab (English)

1 reference

4 November 2017

G Comi

1

1 reference

4 November 2017

R Gold

2

1 reference

4 November 2017

F Dahlke

3

1 reference

4 November 2017

A Sinha

4

1 reference

4 November 2017

P von Rosenstiel

5

1 reference

4 November 2017

D Tomic

6

1 reference

4 November 2017

L Kappos

7

1 reference

4 November 2017

publication date

25 September 2014

1 reference

Multiple Sclerosis Journal

4 November 2017

published in

1 reference

4 November 2017

volume

21

1 reference

4 November 2017

issue

6

1 reference

4 November 2017

page(s)

786-790

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458514549404

21 January 2018

Identifiers

DOI

10.1177/1352458514549404

1 reference

4 November 2017

1 reference